HOLX - Hologic, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
41.12
-0.20 (-0.48%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close41.32
Open41.30
Bid38.98 x 100
Ask42.50 x 200
Day's Range40.95 - 41.37
52 Week Range35.10 - 45.37
Volume1,016,164
Avg. Volume2,098,279
Market Cap11.226B
Beta0.90
PE Ratio (TTM)N/A
EPS (TTM)-0.48
Earnings DateJul 31, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.88
Trade prices are not sourced from all markets
  • NYSE trader: Trump will go easy on drug companies, and stocks should be just fine
    Yahoo Finance Video2 months ago

    NYSE trader: Trump will go easy on drug companies, and stocks should be just fine

    Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss the latest market moves.

  • See what the IHS Markit Score report has to say about Hologic Inc.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Hologic Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Hologic's Cynosure Division Launches TempSure™ Vitalia In North America
    PR Newswire10 days ago

    Hologic's Cynosure Division Launches TempSure™ Vitalia In North America

    MARLBOROUGH, Mass., July 11, 2018  /PRNewswire/ -- Hologic's (HOLX) Cynosure division announced today the North American launch of TempSure™ Vitalia, an FDA-cleared and Health Canada-approved advanced radiofrequency treatment. Birth control, pregnancy, hormones, and aging can change the condition of vaginal tissue over time. TempSure™ Vitalia delivers therapeutic heat to internal and external vaginal tissue to improve local circulation.

  • ACCESSWIRE10 days ago

    Free Pre-Market Technical Recap on Hologic and Three Additional Medical Supplies Stocks

    On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: Becton, Dickinson and Co. (NYSE: BDX), Ekso Bionics Holdings Inc. (NASDAQ: EKSO), Haemonetics Corp. (NYSE: HAE), and Hologic Inc. (NASDAQ: HOLX).

  • 7 S&P 500 Companies Whose Debt Scares Me
    InvestorPlace15 days ago

    7 S&P 500 Companies Whose Debt Scares Me

    The good news, according to S&P Global Ratings, is that U.S. companies had $2.1 trillion of cash at the end of 2017. The bad news is they also had $6.3 trillion in debt for net debt of $4.2 trillion. “These borrowers have $8 of debt for every $1 of cash,” wrote Andrew Chang, the primary credit analyst at S&P Global.

  • PR Newswire18 days ago

    Hologic to Announce Financial Results for the Third Quarter of Fiscal 2018 on Tuesday, July 31, 2018

    MARLBOROUGH, Mass. , July 3, 2018 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2018 on Tuesday, July ...

  • See what the IHS Markit Score report has to say about Hologic Inc.
    Markit21 days ago

    See what the IHS Markit Score report has to say about Hologic Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding HOLX totaled $2.48 billion.

  • See what the IHS Markit Score report has to say about Hologic Inc.
    Markit25 days ago

    See what the IHS Markit Score report has to say about Hologic Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Is It The Right Time To Buy Hologic Inc (NASDAQ:HOLX)?
    Simply Wall St.26 days ago

    Is It The Right Time To Buy Hologic Inc (NASDAQ:HOLX)?

    Hologic Inc (NASDAQ:HOLX) saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqGS. With many analysts covering the large-cap stock, we mayRead More...

  • Hologic's New Panther Fusion System Gets Health Canada Nod
    Zackslast month

    Hologic's New Panther Fusion System Gets Health Canada Nod

    Hologic's (HOLX) receipt of Health Canada approval for the new Panther Fusion system and Panther Fusion assays, for respiratory virus infections, is expected to boost the top line in the near term.

  • CNW Grouplast month

    Hologic's New Panther Fusion® System, Flu and Respiratory Assays Now Approved by Health Canada

    MARLBOROUGH, Mass. , June 18, 2018 /PRNewswire/ -- Hologic, Inc. (HOLX) announced today that it has obtained approval from Health Canada for its new Panther Fusion® system and Panther Fusion assays for respiratory virus infections. The Fusion module offers laboratories the ability to extend the testing capabilities of the existing Panther system. The Panther Fusion module is an in-lab upgrade to the Panther® instrument.  This addition adds the flexibility of PCR (polymerase chain reaction) to the proven performance of TMA (transcription-mediated amplification), which is used by the Panther system.   Offering labs multiple chemistries on a single platform enables further consolidation of lab testing.

  • GlobeNewswirelast month

    LexaGene Names Medical Device Veteran Joseph Caruso to Board of Directors

    LexaGene Holdings Inc. (LXXGF) (LXG.V) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, today announced the appointment of Joseph Caruso, to the Company’s Board of Directors.  “Mr. Caruso is joining LexaGene’s Board of Directors at a pivotal moment for the Company, as we are continuing to push forward with the optimization of our first-of-its-kind prototype for rapid pathogen detection,” said Dr. Jack Regan, LexaGene’s CEO.

  • GlobeNewswirelast month

    Detailed Research: Economic Perspectives on Amphenol, Hologic, Newell Brands, Ciena, SAExploration, and Puma Biotechnology — What Drives Growth in Today's Competitive Landscape

    NEW YORK, June 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amphenol ...

  • ACCESSWIRElast month

    Complimentary Technical Snapshots on Hologic and Three More Medical Supplies Stocks

    Lined up for assessment this morning are these four equities: Haemonetics Corp. (NYSE: HAE), Hill-Rom Holdings Inc. (NYSE: HRC), Hologic Inc. (NASDAQ: HOLX), and Insulet Corp. (NASDAQ: PODD). Shares in Braintree, Massachusetts headquartered Haemonetics Corp. saw a slight decline of 0.61%, ending Monday’s trading session at $93.47.

  • See what the IHS Markit Score report has to say about Hologic Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Hologic Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 14. Index (PMI) data, output in the Healthcare sector is rising.

  • Hologic (HOLX) Down 1.6% Since Earnings Report: Can It Rebound?
    Zacks2 months ago

    Hologic (HOLX) Down 1.6% Since Earnings Report: Can It Rebound?

    Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • ACCESSWIRE2 months ago

    Free Research Report as Hologic’s Revenues Jumped 10.3% and Adjusted EPS Climbed 6%

    LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want access to our free earnings report on Hologic, Inc. (NASDAQ: HOLX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=HOLX. The Company reported its second quarter fiscal 2018 operating and financial results on May 02, 2018. Active-Investors.com is currently working on the research report for BIOLASE, Inc. (NASDAQ: BIOL), which also belongs to the Healthcare sector as the Company Hologic.

  • PR Newswire2 months ago

    Hologic to Webcast Presentations at Upcoming Investor Conferences

    MARLBOROUGH, Mass. , May 29, 2018 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at these upcoming investor conferences: The Jefferies Global Healthcare Conference ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of HOLX earnings conference call or presentation 2-May-18 8:30pm GMT

    Q2 2018 Hologic Inc Earnings Call

  • See what the IHS Markit Score report has to say about Hologic Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Hologic Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 14. Index (PMI) data, output in the Healthcare sector is rising.

  • Associated Press3 months ago

    Tesla and AIG tumble while Kraft Heinz and Kellogg climb

    Stocks that moved substantially or traded heavily Thursday: Tesla Inc., down $16.70 to $284.45 The electric car maker took another big quarterly loss as it struggled to ramp up production of its Model ...

  • Benzinga3 months ago

    Benzinga's Top Analyst Calls From May 3, 2018

    Wayfair Inc (NYSE: W ) - Bank of America on Wednesday upgraded from Neutral To Buy and lifted price target from $90 to $95; Says the company has built "solid scale" in the home goods category. ...

  • Benzinga3 months ago

    Leerink Downgrades Hologic After 'Lower Quality' Q2 Revenue Beat

    Hologic did report a sales beat in it Q2, but it was driven mostly by breast health sales that benefited from distribution acquisitions, Newitter said in a Thursday note. Molecular diagnostics excluding blood screening fell short of expectations due to poor weather trends, Newitter said. A better-than-expected contribution from blood screening yielded a "lower quality" revenue beat, he said.

  • Hologic's (HOLX) Q2 Earnings Meet Estimates, Revenues Top
    Zacks3 months ago

    Hologic's (HOLX) Q2 Earnings Meet Estimates, Revenues Top

    Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q2.

  • Hologic Stock Falls Over 9% on 2Q18 Results, Lower 2018 Guidance
    Market Realist3 months ago

    Hologic Stock Falls Over 9% on 2Q18 Results, Lower 2018 Guidance

    Yesterday, after the market closed, Hologic (HOLX) released its 2Q18 earnings results for the quarter that ended on March 31. The company’s reported revenues exceeded analysts’ estimates, but the adjusted EPS (earnings per share) for the quarter barely met Wall Street estimates. For fiscal 2Q18, the company posted revenues of $789.3 million, representing YoY (year-over-year) revenue growth of ~10.3%.